KJKou-Ichi Jishage

Kou-Ichi Jishage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kou-Ichi Jishage has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Yosuke Kawase

    Chugai Research Institute for Medical Science, Inc. 1-135, Komakado, Gotemba, Shizuoka, Japan

    4 shared publications
  • Otoya Ueda

    Chugai Pharmaceutical Co. Ltd., Research Division, 1-135, Komakado, Gotemba, Shizuoka, Japan

    3 shared publications
  • Atsuhiko Kato

    Chugai Pharmaceutical Co., Ltd., Research Division, Fuji Gotemba Research Labs., 1-135, Komakado, Gotemba, Shizuoka, Japan

    2 shared publications
  • Chisato Goto

    Chugai Research Institute for Medical Science, Inc. 1-135, Komakado, Gotemba, Shizuoka, Japan

    2 shared publications
  • Etsuko Fujii

    Chugai Pharmaceutical Co., Ltd., Research Division, Fuji Gotemba Research Labs., 1-135, Komakado, Gotemba, Shizuoka, Japan

    2 shared publications
  • Hiromi Tateishi

    Chugai Research Institute for Medical Science, Inc. 1-135, Komakado, Gotemba, Shizuoka, Japan

    2 shared publications

Latest Publications

  • Open Access

    Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3–mediated therapeutics

    by Otoya Ueda, Naoko A. Wada, Yasuko Kinoshita, Hiroshi Hino, Mami Kakefuda, Tsuneo Ito, Etsuko Fujii, Mizuho Noguchi, Kiyoharu Sato, Masahiro Morita, et al.

    T cell–mediated immunotherapy is an attractive strategy for treatment in various disease areas. In this therapeutic approach, the CD3 complex is one of the key molecules to modulate T cell functions; however, in many cases, we cannot evaluate the drug candidates in animal experiments because the therapeutics, usually monoclonal antibodies specific to human CD3, cannot react to mouse endogenous Cd3. Although immunodeficient mice transfused with human hematopoietic stem or precursor cells, known as humanized mice, are available for these studies, mice humanized in this manner are not completely immune competent. In this study we have succeeded in establishing a novel mouse strain in which all the three components of the Cd3 complex — Cd3ε, Cd3δ, and Cd3γ — are replaced by their human counterparts, CD3E, CD3D, and CD3G. Basic immunological assessments have confirmed that this strain of human CD3 EDG–replaced mice are entirely immune competent, and we have also demonstrated that a bispecific antibody that simultaneously binds to human CD3 and a tumor-associated antigen (e.g. ERBB2 or GPC3) can be evaluated in human CD3 EDG–replaced mice engrafted with tumors. Our mouse model provides a novel means to evaluate the in vivo efficacy of human CD3–mediated therapy.


  • Open Access

    Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor

    by Otoya Ueda, Hiromi Tateishi, Yoshinobu Higuchi, Etsuko Fujii, Atsuhiko Kato, Yosuke Kawase, Naoko A. Wada, Takanori Tachibe, Mami Kakefuda, Chisato Goto, et al.

    For clinical trials of therapeutic monoclonal antibodies (mAbs) to be successful, their efficacy needs to be adequately evaluated in preclinical experiments. However, in many cases it is difficult to evaluate the candidate mAbs using animal disease models because of lower cross-reactivity to the orthologous target molecules. In this study we have established a novel humanized Castleman's disease mouse model, in which the endogenous interleukin-6 receptor gene is successfully replaced by human IL6R, and human IL6 is overexpressed. We have also demonstrated the therapeutic effects of an antibody that neutralizes human IL6R, tocilizumab, on the symptoms in this mouse model. Plasma levels of human soluble IL6R and human IL6 were elevated after 4-week treatment of tocilizumab in this mouse model similarly to the result previously reported in patients treated with tocilizumab. Our mouse model provides us with a novel means of evaluating the in vivo efficacy of human IL6R-specific therapeutic agents.


  • Open Access

    The Role Of Salivary Glands In Phosphate Homeostasis

    by Tomo Mukai, Hiroko Segawa, Shohei Sasaki, Saori Ohnishi, Yasuko Ishikawa, Naoshi Horiba, Otoya Ueda, Kou-Ichi Jishage, Naoshi Fukushima, Sawako Tatsumi, et al.

    • 1 January 2004
      • Vol. 43  (1) , 21-5

    Comparison of fertility between intracytoplasmic sperm injection and in vitro fertilization with a partial zona pellucida incision by using a piezo-micromanipulator in cryopreserved inbred mouse spermatozoa.

    by Yosuke Kawase, Yukari Aoki, Nobuo Kamada, Kou-Ichi Jishage, Hiroshi Suzuki

    Cryopreservation of mouse spermatozoa has been widely applied for maintenance of transgenic and knockout lines. However, the fertility of cryopreserved spermatozoa from some inbred strains such as C57BL/6 and BALB/c is extremely poor. We have recently reported that a partial zona-pellucida incision by piezo-micromanipulator (ZIP) significantly improves the fertilization rate and subsequent embryonic development after in vitro fertilization (IVF) using cryopreserved C57BL/6 transgenic mouse spermatozoa and that inbred C57BL/6 mice could be produced by intracytoplasmic sperm injection (ICSI). These findings prompted us to compare the efficiency of fertilization and subsequent embryonic development between ICSI and IVF with ZIP (ZIP/IVF) using cryopreserved spermatozoa. In conventional IVF, BALB/cA, C57BL/6J, and B6C3F1 cryopreserved spermatozoa fertilized 19%, 0%, and 51% of oocytes, respectively. The fertilization rates of manipulated oocytes by ICSI versus ZIP/IVF using cryopreserved BALB/cA spermatozoa were 52% versus 68%, cryopreserved C57BL/6J spermatozoa were 43% versus 63%, and cryopreserved B6C3F1 spermatozoa were 58% versus 82%, respectively. In these strains, fertilization rates for ZIP/IVF were significantly higher (P < 0.05) than for other techniques. However, embryonic development to term for oocytes fertilized by cryopreserved spermatozoa was not significantly different between ZIP/IVF and ICSI in C57BL/6J and B6C3F1. The overall efficiency of mouse production in ZIP/IVF was higher than for ICSI and conventional IVF in C57BL/6J and B6C3F1. Furthermore, ZIP/IVF required approximately 3.3 times less manipulation time than did ICSI. Our results indicate that ZIP is a useful assisted reproductive technique for IVF of ova by cryopreserved spermatozoa and improves production in some mouse strains.


  • Role of Lkb1 , the causative gene of Peutz–Jegher's syndrome, in embryogenesis and polyposis

    by Kou-Ichi Jishage, Jun-Ichi Nezu, Yosuke Kawase, Takamitsu Iwata, Miho Watanabe, Akio Miyoshi, Asuka Ose, Kiyoshi Habu, Takei Kake, Nobuo Kamada, et al.

    Peutz–Jeghers syndrome (PJS) is a dominantly inherited human disorder characterized by gastrointestinal hamartomatous polyposis and mucocutaneous melanin pigmentation. LKB1 (STK11) serine/threonine kinase is the product of the causative gene of PJS, which has been mapped to chromosome 19p13.3. However, several studies have produced results that are not consistent with a link between LKB1 gene mutation and PJS. We constructed a knockout gene mutation of Lkb1 to determine whether it is the causative gene of PJS and to examine the biological role of the Lkb1 gene. Lkb1 −/− mice died in utero between 8.5 and 9.5 days postcoitum. At 9.0 days postcoitum, Lkb1 −/− embryos were generally smaller than their age-matched littermates, showed developmental retardation, and did not undergo embryonic turning. Multiple gastric adenomatous polyps were observed in 10- to 14-month-old Lkb1 +/− mice. Our results indicate that functional Lkb1 is required for normal embryogenesis and that it is related to tumor development. The Lkb1 +/− mouse is suitable for studying molecular mechanism underlying the development of inherited gastric tumors in PJS.